Annotated BibliographyThomas Kalinoski
Abhilash,
M., Vidya, A.G., Jagadevi, T. (2009). Bacteriophage Therapy: A War Against
Antibiotic Resistant Bacteria. The
Internet Journal of Alternative Medicine. 7 (1). This
article introduces bacteriophages, their activity, and their use in phage
therapy. It also discusses some of the advantages of phage therapy over
antibiotics, as well as the problems associated with its use. Borysowski, J..
(2008, Sep). Is phage therapy acceptable in the immunocompromised host? International Journal of Infectious Diseases.
12(5), 466-471. from Science Direct. This article examines
the safety of phage therapy, especially in immunocompromised individuals. The
article discusses the possible negative interactions with the immune system,
and the safety of the therapy compared to its effectiveness. Carmody, L. A. (2010,
Jan). Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia
pulmonary infection. The Journal of Infectious Diseases. 201(2),
264-271. from Medline. This article studies
the therapeutic potential for bacteriophages in a mouse model of acute
Burkholderia cenocepacia pulmonary infection. Chhibber, S. (2008). Therapeutic potential of
bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia. Journal
of Medical Microbiology, 57 pp. 1508-1513. This article discusses the study of the use of
bacteriophages to treat the multidrug-resistant Klebsiella pneumonia infection in mice. The mice were treated
with an intranasal inoculation of the bacteria, then a dose of the
bacteriophage treatment at varying times. Fischetti, V. A.
(2008, Oct). Bacteriophage lysins as effective antibacterials. Current
Opinions in Microbiology. 11(5), 393-400. from PubMed. This article
discusses the potential applications of bacterophage lysins in antibacterial
therapy. Lysins are enzymes produced by bacteriophage and break down the
bacterial cell wall. Kropinski,
A. M. (2006, Sep). Phage Therapy- Everything Old is New Again. Medical Microbiology. 17(5), 297-306. from
PubMed. This
article introduces the reader to phage therapy and discusses some of the
applications as well as pitfalls of the use of phages to treat infections. This
article also discusses some of the history behind phage therapy and its
potential role in healthcare in the future. Letkiewicz,
S.. (2010, Nov). The perspectives of the application of phage therapy in
chronic bacterial prostatitis. Fems Immunology and Medical Microbiology. 60(2), 99-112. from ISA
Web of Knowledge. This
article studies the application of bacteriophage therapy to a specific
infection, prostatitis, which has otherwise limited treatment options because
of multi-drug resistance and high relapse rate for the infection. Levin, B., Bull, J. (2004). Population and Evolutionary Dynamics of Phage
Therapy. Nature Review: Microbiology. (2),
166-173. This study examines the evolutionary dynamics of phage and bacteria and
its impact on bacterial resistance. This article also discusses the potential
of phage therapy, and whether it will inevitably suffer the same problems faced
with antibiotics in terms of resistance. Matsuda, T.. (2005, Jun). Lysis-deficient bacteriophage
therapy decreases endotoxin and inflammatory mediator release and improves
survival in a murine peritonitis model. Surgury. 137(6), 639-546.
from ScienceDirect. This article discusses lysis-deficient (LyD) phages that
kill bacteria without lysing it, thus not releasing endotoxin. The experiment
studies the effects of A3 T4 LyD on bacterial peritonitis in mice. Sulakvelidze, A.. (2005, Jun). Phage therapy: an attractive
option for dealing with antibiotic-resistant bacterial infections . Drug
Discovery Today. 10(12), 807-809. from ScienceDirect. This article describes the history of chemotherapy and phage
use. It also describes credible research on the subject and its issues in
gaining acceptance. T4 Bacteriophage [artificially colored electron micrograph],
Retrieved from
Zimecki, M.. (2009,
Aug). Effects of prophylactic administration of bacteriophages to
immunosuppressed mice infected with Staphylococcus aureous. BMC
Microbiology. 17(9), 169-. from PubMed. This article is based
on the research of bacteriophages in the treatment of an infection due to S.
aureous bacteria in mice. This article is specifically focused on use of
bacteriophages on immunosuppressed individuals. Zimecki, M.. (2008, Feb). The concerted
action of lactoferrin and bacteriophages in the clearance of bacteria in
sublethally infected mice. Postepy Hig Med Dosw. 7(62), 42-46. from
PubMed. This article examines whether the combined treatment of infected mice with lactoferrin and bacteriophages may allow significant lowering of the bacteriophage dose needed for effective elimination of E. coli and S. aureous |